Nanosonics Ltd. reported consolidated earnings results for the half year ended December 31, 2011. For the period, the company's sales revenue had grown 271% to $5.08 million from $1.37 million in the prior year, reflecting the rapid expansion of sales of the Trophon EPR, primarily in the North American market. Despite increased costs due the ongoing development of the Trophon EPR, increased investment in manufacturing capacity and business development costs net loss after tax decreased $1.49 million (33%) to $3.01 million from $4.52 million in the previous year. The results show that the company is building sales momentum with its flagship product, Trophon EPR. Net loss attributable to owners of the parent entity was $3.01 million against $4.52 million a year ago. Diluted loss per share was 1.31 cents against 2.00 cents per share for the same period last year. Operating loss before income tax expense was $3.01 million against $4.5 million a year ago. Net cash used in operating activities was $2.84 million against $4.58 million a year ago. Purchase of assets was $0.363 million against $0.708 million a year ago. The company announced that, for the year 2012, the continued improvement in sales revenues is being built on a strong proactive campaign supported by GE Healthcare and increasing word of mouth referral. The company will continue to grow its relationship with GE Healthcare.